SEPN
SepternaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SEPN
Septerna, Inc.
A biotechnology company utilizes its proprietary Native Complex Platform ? Technology has ushered in a new era of orally administered small molecule drugs using G protein coupled receptors (GPCRs).
250 East Grand Avenue, South San Francisco, California 94080
--
Septerna, Inc., was incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, they changed their name to Septerna, Inc. The company is a clinical-stage biotechnology company that has ushered in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, powered by its proprietary Native Complex PlatformTM. Their industrial-scale platform aims to unlock the full potential of GPCR therapies and discover and develop their deep pipeline of product candidates, initially focusing on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Company Financials
EPS
SEPN has released its 2025 Q3 earnings. EPS was reported at 0.18, versus the expected 0.79, missing expectations. The chart below visualizes how SEPN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SEPN has released its 2025 Q3 earnings report, with revenue of 21.50M, reflecting a YoY change of 12113.07%, and net profit of 8.17M, showing a YoY change of 139.82%. The Sankey diagram below clearly presents SEPN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
